J. Lafitte

发表

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

M Paesmans, J. Lafitte, M. Paesmans, 2004, British Journal of Cancer.

The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis

J. Verdebout, J. Lafitte, M. Paesmans, 2002, British Journal of Cancer.

Axonemal dynein intermediate-chain gene (DNAI1) mutations result in situs inversus and primary ciliary dyskinesia (Kartagener syndrome).

J. Lafitte, M. Harricane, P. Bouvagnet, 2001, American journal of human genetics.

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

J. Lafitte, M. Paesmans, T. Berghmans, 2004, British Journal of Cancer.

Critically ill cancer patient’s resuscitation: a Belgian/French societies’ consensus conference

V. Durieux, T. Berghmans, A. Meert, 2021, Intensive Care Medicine.

Surrogate markers predicting overall survival for lung cancer: ELCWP recommendations

J. Lafitte, P. V. Van Schil, P. van Houtte, 2011, European Respiratory Journal.

Has Cox-2 a prognostic role in non-small-cell lung cancer? A systematic review of the literature with meta-analysis of the survival results

J. Lafitte, M. Paesmans, T. Berghmans, 2006, British Journal of Cancer.

The complexity of mucins.

J. Lafitte, M. Lhermitte, G. Lamblin, 1988, Biochimie.

Citation indexes do not reflect methodological quality in lung cancer randomised trials.

J. Lafitte, M. Paesmans, T. Berghmans, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis.

J. Lafitte, M. Paesmans, T. Berghmans, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma.

J. Lafitte, G. Chrousos, S. Wenzel, 1999, American journal of respiratory and critical care medicine.

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

M Paesmans, J P Sculier, J. Verdebout, 2002, European Respiratory Journal.

Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis

J. Verdebout, J. Lafitte, M. Paesmans, 2003, British Journal of Cancer.

Cystic fibrosis and congenital absence of the vas deferens.

J. Lafitte, R. Gervais, J. Rigot, 1991, The New England journal of medicine.

The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature

J. Verdebout, J. Lafitte, M. Paesmans, 2003, British Journal of Cancer.

Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party

J. Lafitte, V. Ninane, M. Paesmans, 2007, British Journal of Cancer.

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients

J. Lafitte, M. Paesmans, E. Steels, 2002, Supportive Care in Cancer.

A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.

J. Lafitte, V. Ninane, M. Paesmans, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer.

J. Lafitte, P. van Houtte, M. Paesmans, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Pronostic factors of synchronous brain metastases from lung cancer.

A. Brichet, J. Lafitte, R. Assaker, 2001, Lung cancer.

Survival is better predicted with a new classification of stage III unresectable non-small cell lung carcinoma treated by chemotherapy and radiotherapy.

T. Berghmans, J. Sculier, G. Koumakis, 2004, Lung cancer.

Evidence for CYP2D6 expression in human lung.

J. Lafitte, C. Spire, D. Marez, 1997, Biochemical and biophysical research communications.

The binding of amikacin to macromolecules from the sputum of patients suffering from respiratory diseases.

J. Lafitte, M. Lhermitte, J. Pommery, 1992, The Journal of antimicrobial chemotherapy.

[VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis].

J. Verdebout, J. Lafitte, M. Paesmans, 2002, Revue des maladies respiratoires.

Massive hemoptysis of pulmonary arterial origin: diagnosis and treatment.

J. Remy, J. Lafitte, L. Lemaitre, 1984, AJR. American journal of roentgenology.

A three-arm phase III randomised trial assessing, in patients with extensive-disease small-cell lung cancer, accelerated chemotherapy with support of haematological growth factor or oral antibiotics

J. Lafitte, V. Ninane, M. Paesmans, 2001, British Journal of Cancer.

A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.

J. Lafitte, V. Ninane, M. Paesmans, 1999, European journal of cancer.